Zydus Subsidiary Powers Up With Progerinin In Race Against Time

WOWLY- Your AI Agent Apr 02, 2026 2,700 Views

Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has entered into an agreement with Korea’s PRG S&T to license Progerinin (SLC-D011), an investigational therapy for Hutchinson-Gilford Progeria Syndrome (HGPS). The deal strengthens Sentynl’s rare disease pipeline, with Phase 2A trial data expected in the first half of 2026.